

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands as an exempted company with limited liability)

(Stock code: 1873)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO CONNECTED TRANSACTION

Reference is made to the announcement of Viva Biotech Holdings (the “**Company**”) dated May 28, 2025 in relation to, among others, the establishment of a limited partnership fund constituting a connected transaction of the Group (the “**Announcement**”). Unless otherwise defined, capitalized terms used herein shall have the same meaning as those defined in the Announcement.

The Company wish to supplement that each of Nanjing High-Quality, Nanjing BPV, Nanjing Yangzi, Nanjing Beilian, Nanjing New Town and Nanjing Gaoxin (being Limited Partners under the Joint Venture Agreement) are ultimately controlled by Nanjing Jiangbei New Area Management Committee (南京江北新區管理委員會), a governmental body in the Jiangbei New Area of Nanjing.

All other information as set out in the Announcement remains unchanged and shall continue to be valid for all purposes. This announcement is supplemental to and should be read in conjunction with the Announcement.

By order of the Board

Viva Biotech Holdings

Mao Chen Cheney

Chairman and Chief Executive Officer

Hong Kong

June 4, 2025

As at the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying and Mr. Ren Delin; two Non-executive Directors, namely, Mr. Wu Yuting and Mr. Wang Stephen Hui; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang